RVTY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.29 | - | - |
| Q2'26 | $1.25 | $1.41 | +13.1% |
| Q1'26 | $1.23 | $1.06 | -13.8% |
| Q4'25 | $1.58 | $1.70 | +7.5% |
| Q3'25 | $1.14 | $1.18 | +3.6% |
| Q2'25 | $1.14 | $1.18 | +3.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $711M | - | - |
| Q2'26 | $723M | $730M | +0.9% |
| Q1'26 | $736M | $711M | -3.4% |
| Q4'25 | $777M | $772M | -0.6% |
| Q3'25 | - | $699M | - |
| Q2'25 | - | $720M | - |
Market Data
RVTY Stock Snapshot
RVTY is currently trading at $114.66, giving Revvity, Inc. a market cap of 12.77B and a P/E ratio of 53.8. Today's range spans $113.73–$115.51, with shares opening at $114.98 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 79/100.
Over the past year RVTY has traded between $81.22 and $118.30 - the current price is +41.2% off the 52-week low and -3.1% from the high.
In the Healthcare peer group, Revvity, Inc. (RVTY) stands out for a BUY signal backed by aligned sentiment - score 86/100, sentiment bullish at 79/100, price $114.66 (near 52-week highs). (P/E: 53.8) With 12.77B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $81.22–$118.30 shows the stock has already proven it can make significant moves.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (79/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $114.66 (near 52-week highs), RVTY's position within the $81.22–$118.30 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Revvity, Inc. (RVTY)
Revvity, Inc., formerly PerkinElmer, operates as a key provider of health science solutions, focusing on technologies and services essential for research, diagnostics, and drug discovery. The company's core offerings encompass instruments, reagents, and software designed to facilitate advanced genetic testing and analysis. These tools are critical for applications ranging from the early detection of genetic disorders to infectious disease testing and comprehensive genomic workflows. Revvity serves a broad customer base, including pharmaceutical giants, academic research institutions, and healthcare providers, underscoring its integral role in the life sciences ecosystem.
The company's strategic emphasis on innovation is evident in its recent introduction of new platforms at SLAS2026, aimed at accelerating drug discovery. Products like the Opera Phenix OptIQ high-content screening system and the EnVision Nexus One multimode plate reader are designed to enhance research efficiency. These advanced systems, alongside the AssayMate workstation, represent Revvity's commitment to providing cutting-edge solutions for complex biological challenges. Such technological advancements are crucial for maintaining a competitive edge in the rapidly evolving diagnostics and research markets.
Financial performance indicates a positive trajectory in earnings per share (EPS) and revenue over the last four reported quarters. Revvity has consistently surpassed EPS estimates, reflecting effective operational execution and demand for its solutions. While revenue shows an upward trend, investors are advised to monitor the impact of new product launches on future earnings growth. Concurrently, potential headwinds such as valuation concerns and market dynamics in specific regions, like China diagnostics, warrant careful consideration in assessing the company's overall outlook.
Diagnostics & Research
Provides essential instruments, reagents, and software for genetic testing and analysis.
Supports critical applications including newborn screening, oncology research, and immunodiagnostics.
Serves a diverse customer base of pharmaceutical companies, research institutions, and healthcare providers.
Drug Discovery Acceleration
Launched new platforms like Opera Phenix OptIQ and EnVision Nexus One at SLAS2026.
These systems aim to enhance high-content screening and multimode plate reading capabilities.
Focuses on accelerating complex drug discovery workflows for its clients.
Financial Performance
Demonstrated consistent EPS growth and beat estimates in all recent quarters.
Revenue trends upwards, supported by demand for its health science solutions.
New product impact and regional market dynamics will influence future earnings.
Market Position
Operates within the Diagnostics & Research industry in the United States.
Formerly known as PerkinElmer, with a history dating back to 1937.
Faces competition and potential market weakness in specific segments like China diagnostics.
Positioning RVTY
Revvity's consistent EPS growth and new product introductions present opportunities for investors. Exposure may be increased following successful integration and demonstrated revenue acceleration from new platforms. Conversely, significant weakness in key diagnostic markets or persistent valuation concerns could warrant a reduction in position size.
Risk Factors
Revvity's risk profile is tied to its innovation pipeline, regulatory environment, and global market dynamics. Investors should monitor the successful integration of new technologies and the company's ability to navigate specific regional market challenges.
- China Diagnostics
Weakness in the China diagnostics market poses a direct threat to Revvity's revenue streams. A slowdown in this key region, driven by economic factors or increased local competition, could negatively impact sales. This risk would materialize if reported sales from China continue to decline or fail to meet growth expectations.
- Product Innovation
Revvity's growth relies heavily on the successful development and adoption of new platforms and technologies. Failure to innovate or commercialize new products effectively could lead to market share erosion. This risk becomes critical if competitors launch superior solutions or if new Revvity products underperform commercially.
- Valuation Concerns
The company's current valuation may present a risk if future growth does not meet investor expectations. High multiples can lead to significant stock price declines if earnings or revenue growth falters. This concern would be amplified if the company misses earnings targets or revises its forward guidance downwards.
- Regulatory Scrutiny
As a provider of health science solutions, Revvity is subject to evolving regulatory standards in its key markets. Changes in regulations concerning diagnostics or drug discovery could increase compliance costs or impact product approvals. This risk would materialize if new regulations are introduced that hinder Revvity's operations or product lifecycles.
Analyst Price Targets for RVTY
The current spread of analyst price targets and ratings for Revvity, Inc. (RVTY).
Reflects the most recently tracked analyst ratings for RVTY and may lag real-time updates. Not a recommendation to buy or sell.
Key Metrics for RVTY
Revvity's performance hinges on innovation in diagnostics and research tools. Investors should monitor key operational and financial metrics to gauge its growth trajectory and market position.
Revenue Growth: Measures the increase in Revvity's total sales quarter-over-quarter and year-over-year. Accelerating revenue growth indicates strong demand for its health science solutions; slowing growth could signal market saturation or competitive pressures. This is crucial for RVTY as it directly impacts profitability and its ability to fund R&D for new technologies.
EPS Growth: Tracks the increase in Revvity's earnings per share. Consistent EPS growth, especially when beating estimates, suggests effective cost management and operational efficiency; declining EPS is a red flag. For RVTY, this metric reflects the company's ability to translate revenue into shareholder value.
New Product Adoption: Assesses the market uptake and revenue contribution from recently launched instruments and reagents, such as the Opera Phenix OptIQ and EnVision Nexus One. Strong adoption validates Revvity's innovation pipeline; weak adoption suggests R&D missteps or poor market fit. This is vital for RVTY's long-term competitive advantage and future growth.
Genetic Testing Volume: Monitors the number of genetic tests and analyses performed using Revvity's platforms and reagents. Higher volumes indicate increased utilization in diagnostics and research; a decline may point to shifts in healthcare trends or competition. This metric is fundamental to RVTY's core business and its impact on early disease detection and genomic workflows.
R&D Investment: Examines the level of capital Revvity allocates to research and development. Increased R&D spending signals a commitment to innovation and future growth; significant cuts could jeopardize its competitive edge. For RVTY, sustained R&D is essential to maintain leadership in the rapidly evolving health sciences sector.
RVTY Recent Earnings History
- Q4 2025
EPS: $1.7 actual vs $1.58 estimate (beat) · Revenue: $772M actual vs $777M estimate
- Q3 2025
EPS: $1.18 actual vs $1.14 estimate (beat) · Revenue: $699M actual
- Q2 2025
EPS: $1.18 actual vs $1.14 estimate (beat) · Revenue: $720M actual
- Q1 2025
EPS: $1.01 actual vs $0.95 estimate (beat) · Revenue: $665M actual
- Q4 2024
EPS: $1.42 actual vs $1.38 estimate (beat) · Revenue: $730M actual
RVTY Competitive Positioning
Revvity, Inc. (RVTY) is tracked alongside these names in Diagnostics & Research on DailyIQ.
What Moves RVTY Stock?
Revvity's stock performance is driven by its innovation in life sciences tools and diagnostic solutions, alongside its financial results and strategic market positioning.
Product Innovation
Revvity recently launched advanced platforms like the Opera Phenix OptIQ and EnVision Nexus One at SLAS2026, aimed at accelerating drug discovery workflows.
These cutting-edge technologies are designed to enhance research capabilities, potentially driving higher adoption rates and revenue growth, which can positively impact stock valuation.
Financial Performance
The company has demonstrated consistent earnings per share growth and an upward trend in revenue over the past four quarters.
Beating EPS estimates in all recent quarters suggests operational efficiency and strong market demand, providing a solid foundation for investor confidence and stock appreciation.
Market Dynamics
While Revvity benefits from strong demand in diagnostics and research, it faces challenges such as valuation concerns and weakness in the China diagnostics market.
Navigating these market-specific headwinds and capitalizing on global opportunities will be crucial for sustained stock performance and mitigating potential downside risks.
Key insight: Revvity's stock is primarily influenced by its ability to innovate and launch new technologies that drive revenue growth, alongside its consistent financial performance. Investors should monitor the adoption of its new platforms and its strategic response to market-specific challenges to gauge future stock trajectory.
Frequently Asked Questions About RVTY
Is Revvity, Inc. (RVTY) stock a good investment?
Revvity's investment appeal often centers on its role in health sciences, providing solutions for research and diagnostics. The company's focus on genetic testing and drug discovery workflows, supported by new technology launches, could drive future growth. Investors may consider the company's consistent EPS growth and revenue trends alongside competitive pressures and market dynamics.
What drives Revvity (RVTY) stock price?
The stock price of Revvity, Inc. is influenced by its performance in the diagnostics and research sectors, particularly the demand for its genetic testing and drug discovery solutions. New product introductions, such as those presented at SLAS2026, and the company's ability to capture market share in key areas like oncology and immunodiagnostics are significant factors. Broader healthcare spending trends and investor sentiment towards health science companies also play a role.
Does Revvity (RVTY) pay a dividend?
Revvity, Inc. currently does not pay a regular dividend to its shareholders. The company has historically focused on reinvesting its earnings back into the business to fund research, development, and strategic initiatives. Investors seeking income may need to consider other investment opportunities or evaluate Revvity's potential for future capital returns if its strategy evolves.
What are the risks of investing in Revvity (RVTY) stock?
Risks associated with Revvity stock include potential competitive pressures within the diagnostics and research markets, as well as macroeconomic factors affecting healthcare spending. Concerns regarding valuation and potential weakness in specific geographic markets, such as China diagnostics, have been noted. The company's reliance on innovation and the successful adoption of new technologies also presents an inherent risk.
How is Revvity's (RVTY) valuation assessed?
Valuation for Revvity, Inc. (RVTY) is often assessed by comparing its price-to-earnings (P/E) ratio to industry averages and its historical multiples. Analysts also consider revenue growth, earnings per share (EPS) trends, and the company's market capitalization relative to its peers. The perceived value of its technology platforms and its position in the growing health sciences market are key components of its valuation.
What is Revvity's (RVTY) investment thesis?
The bull case for Revvity centers on its established position in health sciences, providing critical tools for research, diagnostics, and drug discovery. Continued innovation, as evidenced by new product launches, and consistent EPS growth suggest a pathway for future expansion. The company's ability to capitalize on trends in personalized medicine and advanced genomic workflows could underpin its long-term growth trajectory.
How has Revvity (RVTY) performed recently?
Revvity, Inc. has demonstrated consistent EPS growth over the last four reported quarters, with revenue also trending upwards. The company has a track record of beating EPS estimates, indicating operational strength. Recent news highlights new platform launches aimed at accelerating drug discovery, suggesting a focus on innovation to drive future performance.
What are Revvity's (RVTY) growth catalysts?
Key growth catalysts for Revvity include the successful commercialization of its newly launched platforms, such as the Opera Phenix OptIQ and EnVision Nexus One systems, which aim to enhance drug discovery workflows. Expansion in emerging markets and the increasing demand for advanced genetic testing and diagnostics solutions are also significant drivers. Strategic acquisitions or partnerships could further accelerate its growth.
What is Revvity's (RVTY) competitive landscape?
Revvity operates in a competitive landscape within the health sciences sector, facing rivals in diagnostics, research instruments, and drug discovery services. While its broad suite of offerings provides a competitive advantage, companies like Eli Lilly and Johnson & Johnson, though in different primary industries, represent the broader competitive pressures within the healthcare ecosystem. Continuous innovation and effective market penetration are crucial for maintaining its competitive edge.
Learn More
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).